Pneumonia Vaccine

School of Medicine researchers Elizabeth Norton and Dr. Jay Kolls have developed a nasal spray vaccine to thwart antibiotic-resistant Klebsiella pneumoniae, a leading cause of bacterial pneumonia. They were awarded a National Institute of Allergy and Infectious Diseases contract worth up to $16 million to bring a nasal spray pneumonia vaccine to Phase 1 clinical trial.

Horizontal thumbnail